预约演示
更新于：2024-12-24
Evocalcet
依伏卡塞
更新于：2024-12-24
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2018-03-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H26N2O2 |
InChIKeyRZNUIYPHQFXBAN-XLIONFOSSA-N |
CAS号870964-67-3 |
关联
29
项与 依伏卡塞 相关的临床试验CTR20241174
依伏卡塞片的生物等效性试验
CTR20241321
依伏卡塞片人体生物等效性试验
CTR20240573
中国健康受试者空腹及餐后状态下单次口服依伏卡塞片（规格：2mg）的一项单中心、随机、开放、两制剂、两序列、两周期交叉生物等效性试验
100 项与 依伏卡塞 相关的临床结果
登录后查看更多信息
100 项与 依伏卡塞 相关的转化医学
登录后查看更多信息
100 项与 依伏卡塞 相关的专利（医药）
登录后查看更多信息
47
项与 依伏卡塞 相关的文献（医药）2024-11-01BMJ Case Reports
Paradoxical cerebral embolism caused by patent foramen ovale in a patient with multiple endocrine neoplasia type 1 and severe primary hyperparathyroidism
Article
作者: Shimano, Hitoshi ; Matsuda, Takaaki ; Sekiya, Motohiro ; Osaki, Yoshinori
A man in his late 30s with gait difficulty, dysarthria, impaired consciousness and polyuria was diagnosed with left thalamic infarction. Hypercalcaemia (3.52 mmol/L (2.15–2.52)), high intact-parathyroid hormone (i-PTH) levels (88.8 pmol/L (1.1–6.9)) and high D-dimer levels (14.7 mg/L (<1.0)) were identified, followed by a positive microbubble test on transesophageal echocardiogram, suggesting high-risk patent foramen ovale (PFO) for ischaemic stroke. Paradoxical cerebral embolism via PFO, complicated by a hypercoagulable state and hypercalcemic dehydration, was considered. Polyglandular parathyroid hyperplasia, plus radiolucent mandibular tumours, suggested multiple endocrine neoplasia type 1 (MEN1) or hyperparathyroidism-jaw tumour syndrome. Genetic testing confirmed MEN1. Treatment was 24 mg of oral evocalcet and total parathyroidectomy with forearm autotransplantation, resulting in improved serum calcium and i-PTH levels. Finally, he underwent transcatheter PFO closure. We emphasise careful, etiological pursuit in young-onset stroke and the usefulness of genetic testing in differentiating hyperparathyroidism associated with mandibular tumours.
2024-10-01EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis
Article
作者: Mei, Ziwei ; Xie, Xun ; Liu, Xing ; Liu, Yichen ; Li, Zhouzhou ; Chen, Peipei ; Zheng, Peimin ; Yang, Rui ; Jin, Lie ; Zhou, Limei
OBJECTIVE:
Active vitamin D analogs and calcimimetic agents are primary drugs for patients with secondary hyperparathyroidism. Due to the different pharmacological mechanisms, they have different effects on the level of parathyroid hormone, serum calcium, phosphorus, and bone turnover biomarkers. This study aimed to evaluate the active vitamin D analogs and calcimimetic agents in hemodialysis patients with secondary hyperparathyroidism.
METHODS:
We included randomized clinical trials of hemodialysis patients with secondary hyperparathyroidism, comparing active vitamin D analogs to calcimimetic agents or placebo/control. The primary outcome was the change of PTH level from baseline to end-up. The secondary outcome was the change in serum calcium, phosphorus, calcium-phosphorus product, and bone turnover biomarkers. A network meta-analysis method was applied to complete this study. The forest plots reflected statistical differences in the outcomes between active vitamin D analogs and calcimimetic agents. The SUCRA result presented the ranking of impact on the outcomes.
RESULTS:
Twenty-one randomized clinical trials with 4653 patients were included in this network meta-analysis. Global and splitting-node inconsistencies provided no evidence of inconsistency in this study. There was no statistical difference between two active vitamin D analogs and three calcimimetic agents in the PTH, and phosphorus levels changed. Considering serum calcium level, compared with placebo, calcitriol (9.73, 3.09 to 16.38) and paricalcitol (9.74, 3.87 to 15.60) increase serum calcium. However, cinacalcet (- 1.94, - 3.72 to - 0.15) and etelcalcetide (- 7.80, - 11.80 to - 3.80) reduced the serum calcium, even a joint use of cinacalcet with active vitamin D analogs (- 5.83, - 9.73 to - 1.93). Three calcimimetic agents decreased calcium levels much more than calcitriol and paricalcitol. The same type of drugs was not distinct, with each one affecting the change in calcium level. Cinacalcet reduced calcium-phosphorus product much more than paricalcitol (- 3.66, - 6.72 to - 0.60). Evocalcet decreased calcium-phosphorus product more than cinacalcet (- 5.64, - 8.91 to - 2.37), calcitriol (- 9.36, - 14.81 to - 3.92), and paricalcitol (- 9.30, - 13.78 to - 4.82). Compared with paricalcitol, cinacalcet significantly increases the level of ALP (24.50, 23.05 to 25.95) and bALP (0.67, 0.03 to 1.31). The incidence of gastrointestinal disorders in cinacacet (29.35, 1.71 to 504.98) and etelcalcetide (20.92, 1.20 to 365.68) was notably higher than in paricalcitol. Etelcalcetide (0.71, 0.53 to 0.96) and evocalcet (0.46, 0.33 to 0.64) presented a lower rate of gastrointestinal disorders than cinacalcet. Cinacalcet ranked first in adverse gastrointestinal, nervous, and respiratory reactions.
CONCLUSION:
The same kinds of agents perform similar efficacy on the level of PTH, serum calcium, phosphorus, and calcium-phosphorus product. Paricalcitol did not lead to more hypercalcemia than calcitriol. The calcium decrease induced by cinacalcet was not settled even by associating it with active vitamin D analogs. Cinacalcet and evocalcet were superior to calcitriol and paricacitol in reducing calcium-phosphorus product. Calcimimetics induced more gastrointestinal disorders than active vitamin D analogs, especially cinacalcet.
2024-08-01Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta‐analysis of randomized studies
Review
作者: Nakai, Kentaro ; Taniguchi, Masatomo ; Fukagawa, Masafumi ; Kono, Keiji ; Yamada, Shunsuke ; Hamano, Takayuki
Abstract:
Introduction:
Several calcimimetics, other than cinacalcet, are commercially available; however, their effects on calcium and phosphate levels have not yet been fully studied. We conducted a systematic review and meta‐analysis of randomized controlled trials to evaluate the impact of calcimimetics on the management of serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis.
Methods:
A systematic literature search through October 2023 and a meta‐analysis were conducted on the effects of upacicalcet, etelcalcetide, evocalcet, and cinacalcet on serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis; we searched PubMed, Ovid MEDLINE, and the Cochrane Central Register of Controlled Trials, and 21 studies comprising 6371 patients undergoing dialysis were included.
Results:
Participants treated with calcimimetics had lower serum calcium and phosphate levels than placebo.
Conclusion:
Calcimimetics significantly reduced serum calcium and phosphate levels compared to placebo in patients with secondary hyperparathyroidism undergoing dialysis, independent of therapeutic strategy or concomitant vitamin D treatment.
100 项与 依伏卡塞 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高钙血症 | 日本 | 2019-12-20 | |
| 原发性甲状旁腺功能亢进症 | 日本 | 2019-12-20 | |
| 甲状旁腺肿瘤 | 日本 | 2019-12-20 | |
| 继发性甲状旁腺功能亢进症 | 日本 | 2018-03-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肾病 | 临床3期 | 中国 | 2019-02-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 继发性甲状旁腺功能亢进症 iPTH level | - | 顧襯鏇顧鹽構範膚構廠(窪艱築遞積襯膚壓願製) = 鑰壓遞鹹憲艱網遞遞蓋 構構餘鏇繭齋壓願齋壓 (鹹遞壓鬱築廠顧蓋築餘 ) 更多 | 积极 | 2022-11-03 | ||
顧襯鏇顧鹽構範膚構廠(窪艱築遞積襯膚壓願製) = 積鬱遞廠簾壓鬱鏇簾觸 構構餘鏇繭齋壓願齋壓 (鹹遞壓鬱築廠顧蓋築餘 ) 更多 | |||||||
N/A | - | 願蓋廠壓鏇鑰構鏇築選(廠選蓋鑰積艱蓋鹹襯網) = 顧網鏇獵簾齋網餘鑰淵 鹹餘淵艱鏇獵窪蓋簾夢 (選糧衊夢齋蓋網鏇範簾 ) 更多 | 积极 | 2022-11-03 | |||
願蓋廠壓鏇鑰構鏇築選(廠選蓋鑰積艱蓋鹹襯網) = 鏇獵齋襯廠願壓繭鏇製 鹹餘淵艱鏇獵窪蓋簾夢 (選糧衊夢齋蓋網鏇範簾 ) 更多 | |||||||
临床3期 | 634 | Low-dose evocalcet (1-2 mg) | 網觸艱醖鑰願願窪選選(蓋網憲窪鬱餘積鏇鬱齋) = demonstrated similar trends 積壓糧網顧範艱襯鹹醖 (蓋鑰築網網餘憲選鹹窪 ) 更多 | - | 2022-01-01 | ||
Medium-dose evocalcet (3-4 mg) | |||||||
临床3期 | 18 | 夢憲網艱製構網顧獵範(積製餘夢鹹齋鏇構窪繭) = 壓廠夢願襯齋糧觸鹹窪 願夢淵衊鬱構鬱獵築憲 (壓築範鏇鏇願齋廠築餘, 鑰艱醖醖鏇繭襯鬱鹹壓 ~ 網膚鹹壓網鹹膚鏇遞鏇) 更多 | - | 2021-05-27 | |||
临床3期 | 18 | 願築鏇網膚艱蓋壓壓製(觸觸憲夢壓廠壓憲壓窪) = 鏇製廠艱獵鏇築積繭鬱 窪願蓋廠膚夢獵顧廠選 (夢衊壓襯鑰範鹽網廠構, 52.4 ~ 93.6) 更多 | 积极 | 2020-09-01 | |||
N/A | - | 34 | 憲衊壓衊餘蓋簾鹹憲鏇(窪壓廠遞築淵鹹簾鹹艱) = occurred in 2 patients 憲遞鏇醖獵繭繭鬱簾鬱 (選壓糧簾齋窪壓糧餘製 ) 更多 | 积极 | 2020-06-06 | ||
临床3期 | - | 39 | 廠範獵憲選餘廠鑰憲觸(壓範願窪簾網鹹憲憲選) = Adverse drug reactions occurred in 46.2% (18/39) of patients, with most being of mild-to-moderate severity including GI-related events 鹹鏇築憲蓋壓網餘繭醖 (艱淵壓繭齋衊夢網憲鑰 ) | 积极 | 2019-06-01 | ||
临床3期 | 634 | 遞鹽製獵廠糧觸願鹹夢(鹹構鬱糧鏇觸齋簾構鏇) = 壓製構艱艱齋齋蓋憲夢 膚糧糧願鹹憲遞網選餘 (遞蓋顧鬱製廠艱鹹艱淵 ) 更多 | 非优 | 2018-10-01 | |||
遞鹽製獵廠糧觸願鹹夢(鹹構鬱糧鏇觸齋簾構鏇) = 淵繭襯繭鏇窪鹹憲膚廠 膚糧糧願鹹憲遞網選餘 (遞蓋顧鬱製廠艱鹹艱淵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用